Medindia

X

Frost & Sullivan Web Conference on the European Melanoma Skin Cancer Market: Will the Drugs in Pipeline Deliver?

Tuesday, May 18, 2010 Research News J E 4
Advertisement


LONDON, May 18 There are only two FDA/EMEA approved drugs currently available for treating advanced melanoma. The available drugs, however, are not completely effective and have adverse effects. Unmet needs of patients, especially those with advanced melanoma are therefore quite high and have led to a low drug adoption and market growth over the years. The future looks brighter though, with a few promising drugs in pipeline for advanced melanoma.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

In its upcoming web conference taking place on Tuesday, 25th May 2010, at 3 p.m. GMT Frost & Sullivan will focus on the European Melanoma Skin Cancer Market. Industry Analyst, Ranjith Gopinathan, will present an analysis of latest trends and developments in the market, competitive factors as well as challenges and strategic recommendations.

Highlights of the briefing include analyses of key current therapies, pipeline drugs and market dynamics in melanoma therapeutics.

To participate in this complimentary briefing, please email Katja Feick at katja.feick@frost.com with your full contact details. Upon receipt of the above information, a registration link will be e-mailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

This briefing will benefit pharmaceutical companies, biotech companies, contract research organizations, investment banks, healthcare providers and hospitals by discussing current trends and providing forward projections for the European Melanoma Skin Cancer Market.

"Drugs currently available for advanced melanoma are not fully effective and have adverse effects. Consequently, the unmet needs of patients, especially those with advanced melanoma are quite high. The market therefore needs to focus on the current drugs in pipeline in order to stimulate market growth and a higher drug adoption in the future," concludes Mr. Gopinathan.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Contact: Katja Feick Corporate Communications - Europe P: 0049 (0) 69 77 0 33 43 F: 0049 (0) 69 23 45 66 E: katja.feick@frost.com

SOURCE Frost & Sullivan
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
China Sky One Medical Announces First Quarter 2010...
S
Infosys Technologies Supports Air Liquide With Bus...